-
Product Insights
New![]()
Net Present Value Model: AC Immune SA’s ACI-35
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Madura AC Upstream Project , Indonesia
Madura AC upstream project is located in East Java, Indonesia. The upstream project is owned by Husky-CNOOC Madura Ltd. It will be operated by Husky-CNOOC Madura Ltd. The project is currently in the planned stage and is expected to start operations in 2023. Madura AC Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Follicular Lymphoma Drug Details: AC-0676 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-00058 in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AC-00058 in Rheumatoid ArthritisDrug Details:AC-058 (AC-0058TA) is under development for the treatment of systemic lupus erythematosus...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-203 in Epidermolysis Bullosa
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AC-203 in Epidermolysis BullosaDrug Details:Diacerein (AC-203) is under development for the treatment of epidermolysis bullosa simplex....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACE-1334 in Lung Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACE-1334 in Lung Disease Drug Details: ACE-1334 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACE-1702 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACE-1702 in Solid Tumor Drug Details: ACE-1702 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Mantle Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Mantle Cell Lymphoma Drug Details: AC-0676 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACE-1334 in Systemic Sclerosis (Scleroderma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACE-1334 in Systemic Sclerosis (Scleroderma) Drug Details: ACE-1334 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-699 in Metastatic Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AC-699 in Metastatic Breast Cancer Drug Details:AC-699 is under development for the treatment of estrogen receptor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: AC-0676 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Diffuse Large B-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Diffuse Large B-Cell Lymphoma Drug Details: AC-0676 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details: AC-0676 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Refractory Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details: AC-0676 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Marginal Zone B-cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Marginal Zone B-cell Lymphoma Drug Details: AC-0676 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACE-1831 in B-Cell Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ACE-1831 in B-Cell Non-Hodgkin Lymphoma Drug Details:ACE-1831 is under development for the treatment of CD20-positive B-cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-0176 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AC-0176 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:ACÂ-0176 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACE-1334 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACE-1334 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drug Details: ACE-1334 is under...
-
Welcome Grp – Pasadena AC Hotel by Marriott – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Welcome Grp – Pasadena AC Hotel by Marriott – California report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AC-699 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AC-699 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug Details:AC-699...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.